bachelor's at Farmácia Bioquímica from Fac Farmácia e Odontologia de Ribeirão Preto da Universidade São Paulo (1978), master's at Pharmacy from Universidade de São Paulo (1988) and doctorate at Farmácia e Bioquímica from Universidade de São Paulo (1994). Has experience in Pharmacology, focusing on Clinical Farmacology, acting on the following subjects: enantiomers, pharmacokinetics, plasma, analysis and metabolism. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
The present project brings together clinical pharmacokinetics and pharmacogenetics studies in infectious diseases caused by bacteria, parasites or viruses, in which the inflammatory component is predominant. Subproject 1 elaborates pharmacokinetic-pharmacodynamic (PK-PD) models of antibiotics in patients with tuberculosis including data from plasma and macrophages infected with M. tubercu…
Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease with prevalence of 20-150 cases per 100,000 inhabitants/population. Cardiovascular diseases are major causes of morbidity and mortality in patients with SLE, for which statins have shown to be the most effective strategy in the treatment of dyslipidemia and prevention of atherosclerosis. Classically, statins a…
Oxcarbazepine (OXC) is a drug indicated for the treatment of partial seizures or generalized tonic-clonic seizures in adults and children. The metabolite 10-hydroxy-10 ,11-dihydro-carbazepina (MHD) has pharmacological activity, has a chiral center at position 10, with the enantiomers (S )-(+)- and R-(-)-MHD. The MHD is a substrate of P-glycoprotein (Pgp), an efflux transporter present in …
(Only some records are available in English at this moment)
The study aims to develop pharmacokinetic-pharmacodynamic (PK-PD) models of the antibiotics rifampicin, isoniazid, pyrazinamide and ethambutol in macrophages derived from human monocytes of THP-1 lineage infected and not infected with M. tuberculosis H37Rv strains. Macrophage PK-PD data from antibiotics will be incorporated into population pharmacokinetic models in plasma of tuberculosis …
The thematic project called Clinical pharmacokinetics in infectious diseases brings together 06 subprojects of relevance in precision medicine. Subprojects 1, 3 and 6 cover the development of population pharmacokinetic (popPK) models, which generate estimates of the inter-individual variability of pharmacokinetic parameters, as well as evaluate the effect of individual characteristics, su…
Infections associated with high plasma concentrations of pro-inflammatory cytokines alter the expression/activity of drug transporters, among which, the organic anion transporters (OATs) 1 and 3 are of fundamental importance in the excretion and consequently in the medication dosing regimen. However, little is knows about the influence of inflammation associated with a kidney infection, e…
(Only some records are available in English at this moment)
Pregnancy and inflammation (due to infectious diseases) are each known to alter drug pharmacokinetics (PK) by changing the expression and activity of transporters and/or drug-metabolizing enzymes (e.g. CYPs). Quantifying changes in drug PK caused by pregnancy and/or cytokines (elevated during inflammation) is important for rational design of dosing regimens of drugs for pregnant women wit…
Tuberculosis (TB) is a major cause of ill health and one of the leading causes of death worldwide. Until the coronavirus (COVID-19) pandemic, TB was the leading cause of death from a single infectious agent, ranking above HIV/AIDS. Rifampicin, isoniazid, pyrazinamide, and ethambutol are currently the first-line anti-tuberculosis drugs (FLATDs) that are administered simultaneously accordin…
The study aims to investigate the influence of age, hormonal status, CYP2D6, CYP3A and P-gp in vivo activities and genetic polimorphisms on tamoxifen kinetic disposition and metabolism in breast cancer patients. Thus, two groups of patients were defined according to age and hormonal status, pre-menopausal group (age < 50 years) and postmenopausal group (age > 60 years). Blood samples were…
(Only some records are available in English at this moment)
| 20 / 9 | Completed research grants |
| 38 / 21 | Completed scholarships in Brazil |
| 6 / 6 | Completed scholarships abroad |
| 64 / 36 | All research grants and scholarships |
| Associated processes | |
CV Lattes
ORCID